Observation of Initial Procalcitonin and the Clinical Course of Patients With Acute Respiratory Tract Infections

Respiratory Tract Infections Clinical Trial

Official title:

Observation of the Initial Procalcitonin Values and the Clinical Course of Patients With Acute Respiratory Tract Infections at General Medical Practices in Greater Hannover

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00827060
• Other study ID #: HannoverPro
• Status: Completed
• Phase: N/A
• First received: January 21, 2009
• Last updated: January 27, 2009
• Start date: December 2006
• Est. completion date: September 2007

Study information

• Verified date: January 2009
• Source: Hannover Medical School
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Observational

Clinical Trial Summary

Observation of the initial Procalcitonin values and the clinical course of consecutively included patients with Acute Respiratory Tract Infections at general medical practices in greater Hannover.

Description:

Primary endpoint:

• initial Procalcitonin values of patients with Acute Respiratory Tract Infections

Secondary endpoints:

• correlation of initial Procalcitonin values to classify Acute Respiratory Tract Infections

• correlation of initial Procalcitonin values to subjective severity of Acute Respiratory Tract Infections

• correlation of initial Procalcitonin values to antibiotic- prescriptions

• correlation of initial Procalcitonin values to frequency of admission to hospital

• correlation of initial Procalcitonin values to frequency of referrals (radiology, pneumology)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 702
• Est. completion date: September 2007
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• written informed consent

• all types of respiratory tract infection according to investigator´s diagnosis

Exclusion Criteria:

• pretreatment with antibiotics in the past 2 weeks

• portal hypertension

• Major surgeries or multiple trauma which require hospitalization, in previous 4 weeks

• Autoimmune disease and systemic diseases (lupus erythematodes, wegener´s disease)

• Peritoneal dialysis

• Acute treated or recently operated medullary c-cell-carcinoma, SCLC, carcinoid

• Other inflammatory diseases (e.g. urinary tract infection, pyelonephritis, pancreatitis

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Respiratory Tract Infections

Locations

Country	Name	City	State
Germany	Medical School Hannover, Department Pneumology	Hannover

Sponsors (1)

Lead Sponsor	Collaborator
Hannover Medical School

Country where clinical trial is conducted

Germany,